Section Arrow
OCS.NASDAQ
- Oculis Holding AG
Quotes are at least 15-min delayed:2026/05/31 11:20 EDT
Regular Hours
Last
 22.705
-6.945 (-23.42%)
Day High 
29.645 
Prev. Close
29.65 
1-M High
34.475 
Volume 
2.86M 
Bid
15
Ask
15.01
Day Low
20.01 
Open
29.3 
1-M Low
25.91 
Market Cap 
1.79B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 29.41 
20-SMA 29.64 
50-SMA 27.74 
52-W High 34.475 
52-W Low 16 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.69/-1.96
Enterprise Value
1.79B
Balance Sheet
Book Value Per Share
4.15
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.1172-0.0468-28.54%-- 
REPLReplimune Group8.69+4.01+85.68%-- 
CDTCDT Equity Inc.1.04+0.0899+9.46%-- 
CMNDClearmind Medicine Inc.3.58+1.13+46.12%-- 
OTLKOutlook Therapeutics0.73-0.01-1.35%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.